EFFECTS OF ICOSAPENT ETHYL ON VASCULAR REGENERATIVE CELLS IN INDIVIDUALS WITH ELEVATED TRIGLYCERIDES: INSIGHTS FROM THE IPE-PREVENTION CARDIOLINK-14 TRIAL
Ehab Bakbak(The University of Queensland), Siddharth Verma(Toronto Public Health), David Hess(Western University), L.A. Leiter, A. Krishnaraj(Toronto Public Health), Kristin Terenzi(Toronto Public Health), Daniella C. Terenzi(St. Michael's Hospital), B. Bari(Toronto Public Health), Allison Quan(Toronto Public Health), Brian Park(Toronto Public Health), Yi Pan(First Affiliated Hospital of Xi'an Jiaotong University), Hock Luen Teoh(National University Health System), C. Mazer(Toronto Public Health), A. Bakbak(Toronto Public Health), Deepak L. Bhatt(Mount Sinai Hospital)
Cited by 0
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k
A Controlled Trial of Renal Denervation for Resistant Hypertension
|New England Journal of Medicine|2014|2.2k
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
|New England Journal of Medicine|2015|2k